Deallus white papers

The latest white papers from Deallus pharmaceutical and life science industry experts

Antimicrobial Resistance

2021-05-12T11:56:09+01:00White Paper|

Lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR). As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further - and larger scale - action is needed. We take a look at what pharma and the larger healthcare industry needs to do in order to combat this looming threat.

Read More

Copay Accumulator Programs & Pharma

2021-05-12T11:56:49+01:00White Paper|

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems. The newest stratagem in this push and pull is the copay accumulator program, or CAP. We take a closer look at CAPs and how they might affect your brand in the near future.

Read More

Competitive Intelligence in an Agile World

2019-11-08T14:34:37+00:00White Paper|

Adapting competitive intelligence functions to an increasingly complex pharma landscape. This White Paper explores the concept of agile working for the pharma world, delving into the opportunities and challenges that arise for Competitive Intelligence teams and managers as working environments adapt to find success in a more dynamic, uncertain, and fast-paced environment.

Read More

Purchasing a Pipeline

2019-11-08T14:30:03+00:00White Paper|

Perils, pitfalls, and priorities in asset acquisition. In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

Read More

The Three A’s of Launch Readiness

2020-02-12T11:48:23+00:00White Paper|

Drug launch failures happen more frequently than pharma companies care to admit. Anticipate, Adapt and Align - the three A’s of successful pharma launch strategy. To understand and implement them requires strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Read More
Deallus LinkedIn Deallus YouTube
Go to Top